drugset / Trial / NCT03699475
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
RandomizedSequentialOpen-labelTreatment
Summary
This study compares the safety and effectiveness of giving rivogenlecleucel (BPX-501 T cells) to patients with AML or MDS post haploidentical hematopoietic stem cell transplant compared to post-transplant cyclophosphamide.
Timeline
- Start
- 2018-12-27
- Primary completion
- 2019-07-23
- Completion
- 2019-07-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclophosphamide | Other / unclassified | — | — |
| Subject | rivogenlecleucel | Cell therapy | 3e+06 cells/kg | Other |
| Background | Rimiducid | Other / unclassified | — | — |